Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: economic results from a pragmatic cluster randomised trial by Bhattarai, Nawaraj et al.
Northumbria Research Link
Citation:  Bhattarai,  Nawaraj,  Price,  Christopher,  McMeekin,  Peter,  Javanbakht,  Mehdi,  Vale,  Luke, 
Ford, Gary A. and Shaw, Lisa (2021) Cost-effectiveness of an enhanced Paramedic Acute Stroke 
Treatment Assessment (PASTA) during emergency stroke care: economic results from a pragmatic 




This  version  was  downloaded  from  Northumbria  Research  Link: 
http://nrl.northumbria.ac.uk/id/eprint/45791/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to access 
the University’s research output. Copyright © and moral rights for items on NRL are retained by the 
individual author(s) and/or other copyright owners.  Single copies of full items can be reproduced, 
displayed or performed, and given to third parties in any format or medium for personal research or 
study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, 
title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata 
page. The content must not be changed in any way. Full items must not be sold commercially in any  
format or medium without formal permission of the copyright holder.  The full policy is available online: 
http://nrl.northumbria.ac.uk/pol  i cies.html  
This  document  may differ  from the  final,  published version of  the research  and has been made 
available online in accordance with publisher policies. To read and/or cite from the published version 
of the research, please visit the publisher’s website (a subscription may be required.)














Cost-effectiveness of an enhanced Paramedic Acute Stroke 
Treatment Assessment (PASTA) during emergency stroke 
care: economic results from a pragmatic cluster randomised 
trial   
Journal: International Journal of Stroke
Manuscript ID IJS-12-20-8751.R1
Manuscript Type: Research
Date Submitted by the 23-Jan-2021






Complete List of Authors: Bhattarai, Nawaraj; Newcastle University, Health Economics Group, 
Population Health Sciences Insitutute
Price, Christopher; Newcastle University, Stroke Research Group, 
Population Health Sciences Institute
McMeekin, Peter; Northumbria University, School of Health, Community 
and Education Studies
Javanbakht, Mehdi; Newcastle University, Health Economics Group, 
Population Health Sciences Institute
Vale, Luke; Newcastle University, Health Economics Group, Population 
Health Sciences Institute
Ford, Gary; Oxford University, Medical Sciences Division
Shaw, Lisa; Newcastle University, Stroke Research Group, Population 
Health Sciences Insitute
Keywords:
cost-effectiveness, cluster randomised controlled trial, Thrombolysis, 
paramedic, ambulance, Stroke
 
Page 1 of 14




Page 1 of 12
Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment 
(PASTA) during emergency stroke care: economic results from a pragmatic cluster 
randomised trial   
Nawaraj Bhattarai1, Christopher I. Price2, Peter McMeekin3, Mehdi Javanbakht1, Luke Vale1, Gary A. Ford2, 4 
Lisa Shaw2
1 Health Economics Group, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
UK.
2 Stroke Research Group, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
UK.
3 Faculty of Health & Life Sciences, Northumbria University, Newcastle upon Tyne, UK.
4 Medical Sciences Division, University of Oxford, and Oxford University Hospitals NHS Foundation Trust, 
Oxford, UK.
Key words: Stroke; Cost-effectiveness; cluster randomised controlled trial; thrombolysis; paramedic; 
ambulance
Word count: 4321
Tables and Figures: 
Table 1. Cost-effectiveness of PASTA pathway versus Standard Care
Figure 1: Cost-effectiveness plane –Base case analysis
Figure 2: Cost effectiveness acceptability curve- Base case analysis
Figure 3. Cost-Effectiveness plane: compliant hospitals
Figure 4. Cost-effectiveness plane: non-compliant hospitals
Page 2 of 14




Page 2 of 12
Abstract
Background: The Paramedic Acute Stroke Treatment Assessment (PASTA) trial evaluated an enhanced 
emergency care pathway which aimed to facilitate thrombolysis in hospital. A pre-planned health economic 
evaluation was included. The main results showed no statistical evidence of a difference in either thrombolysis 
volume (primary outcome) or 90-day dependency. However, counter-intuitive findings were observed with the 
intervention group showing fewer thrombolysis treatments but less dependency.
Aims: Cost-effectiveness of the PASTA intervention was examined relative to Standard Care (SC). 
Methods: A within trial cost-utility analysis estimated mean costs and quality adjusted life years (QALYs) over 
90 days’ time horizon. Cost were derived from resource utilisation data for individual trial participants. QALYs 
were calculated by mapping modified Rankin scale scores to EQ-5D-3L utility tariffs. A post-hoc subgroup 
analysis examined cost-effectiveness when trial hospitals were divided into compliant and non-compliant with 
recommendations for a stroke specialist thrombolysis rota.
Results: The trial enrolled 1214 patients: 500 PASTA and 714 SC. There was no evidence of a QALY difference 
between groups [0·007 (95%CI -0·003 to 0·018)] but costs were lower in the PASTA group [-£1473 (95%CI: -
£2736 to -£219)]. There was over 97.5% chance that the PASTA pathway would be considered cost-effective. 
There was no evidence of a difference in costs at  seven thrombolysis rota compliant hospitals but costs at eight 
non-complaint hospitals costs were lower in PASTA with more dominant cost-effectiveness. 
Conclusions: Analyses indicate that the PASTA pathway may be considered cost-effective, particularly if 
deployed in areas where stroke specialist availability is limited.
Trial Registration: ISRCTN12418919 www.isrctn.com/ISRCTN12418919
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INTRODUCTION 
Intravenous thrombolysis for ischaemic stroke is a cost-effective treatment, but large variations in provision 
exist.1, 2 Previous studies have described improvements in the volume and/or speed of treatment following the 
introduction of ambulance pre-notification,3 multidisciplinary training4 and a higher priority response for 
suspected stroke,5 but none have reported the economic impact of a pre-hospital intervention intended to promote 
thrombolysis delivery.  
The Paramedic Acute Stroke Treatment Assessment (PASTA) multicentre cluster randomised controlled trial 
examined whether an enhanced paramedic emergency stroke assessment pathway for patients presenting within 
4 hours of stroke onset could improve thrombolysis volume (primary outcome) when compared to standard care 
(SC).6,7 Secondary outcomes included dependency at day 90 after stroke (modified Rankin Score (mRS)) and 
resource utilisation data for a pre-planned health economic analysis. The PASTA intervention comprised 
additional prehospital information collection, a structured hospital handover, practical assistance after handover, 
a pre-departure care checklist, and clinician feedback. 
Although there was no statistical evidence of a difference between the trial groups for the proportion of patients 
who received thrombolysis (primary outcome), contrary to the anticipated effect of the intervention, less people 
received treatment in the PASTA group [PASTA: 197/500 (39·4%) versus SC: 319/714 (44·7%); adjusted Odds 
Ratio (aOR) 0·81 (95%CI 0·61 to 1·08); p=0·15]7. There was also no statistical evidence of a difference between 
the trial groups in dependency at day 90 after stroke (modified Rankin Score (mRS)) grades 3-6), however, 
counter-intuitive to the lower thrombolysis rate, fewer patients were dependent in the PASTA group [PASTA: 
313/489 (64.0%) versus SC: 461/690 (66.8%); aOR 0.86 (95% CI 0.60 to 1.20); p = 0.39]. These unexpected 
findings led to a post-hoc analysis to explore how stroke specialist availability impacted upon thrombolysis 
treatment. At 8/15 trial hospitals that were not fully compliant with a national recommendation for specialist input 
into all thrombolysis decisions, there was a significant 9.8% r duction in thrombolysis in the PASTA group 
compared to SC [99/276 (35·9%) PASTA versus 105/230 (45·7%) SC; unadjusted OR 0·67 (95%CI 0·47 to 0·95); 
p=0·03].  Whereas for the 7/15 hospitals that were compliant there was no evidence of a difference in thrombolysis 
rates [98/224 (43·8%) PASTA versus 214/484 (44·2%) SC; unadjusted OR 0·98 (95%CI 0·71 to 1·35); p=0·91]. 
We proposed a hypothesis that structured handover of additional information and/or a multidisciplinary checklist 
improved the selection of patients for thrombolysis, particularly in hospitals with reduced specialist availability7.  
Cost-effectiveness results showing a similar pattern would be consistent with this theory
AIM
This manuscript reports the pre-planned cost-effectiveness analysis of the PASTA intervention and analyses for 
the two post-hoc subgroups defined by local specialist availability.
METHODS
PASTA trial design summary
The PASTA trial protocol is reported elsewhere.6, 7 In summary, a pragmatic multicentre cluster randomised 
controlled trial was hosted by three UK ambulance services (North East, North West and Wales) and 15 
Hyperacute Stroke Units (HASUs). Clusters were individual paramedics based within ambulance stations pre-
randomised to PASTA training or continuing SC. Paramedics at PASTA stations had to successfully complete 
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training prior to their involvement in the trial (accessed online). Paramedics at SC stations were advised that their 
routinely recorded clinical data would be used in a research study.
Patients were identified and recruited to the trial by hospital staff after completion of the thrombolysis assessment 
in participating HASUs. Eligible patients were those where a hospital specialist confirmed a stroke diagnosis and 
a study paramedic had attended within 4 hours of symptom onset. Written consent was obtained. The primary 
outcome was the proportion of patients receiving thrombolysis. Secondary outcomes included key time intervals 
across the emergency stroke pathway and day 90 mRS.  The study sample size calculation  was 1149 participants 
which provided 90% power to detect a change from 43% to 53% of study eligible patients receiving thrombolysis. 
The National Research Ethics Committee North East - Newcastle and North Tyneside 1 (reference 15/NE/0309) 
approved the study.
Resource use and costs
Resource use data for each patient was collected using case report forms and questionnaires. Resource use 
included: PASTA pathway training time (PASTA group only), ambulance time from ‘on-scene’ to ‘clear’, acute 
assessments and treatments, length of stay in hospital, post-discharge rehabilitation, social services involvement 
(paid carers at home and in social care settings) and hospital readmissions. Unit costs were derived from routine 
sources for the NHS and social care,8,9 and other published sources. Details are reported in Table S1 and S2, 
supplementary file.  Where necessary the unit costs were inflated to 2017/18 costs using the Hospital and 
Community Health Services (HCHS) pay and price inflation indices.10 Costs are presented in UK Sterling Pounds. 
The total cost for each participant was calculated as the sum of a number of cost components (e.g ambulance time, 
inpatient care cost, social care cost).
Utilities and QALYs
Utility values were generated by mapping day 90 mRS scores to EQ-5D-3L values11 using previously reported 
algorithms.11, 12 Where there were missing 90 day mRS scores, routinely captured discharge mRS scores were 
carried forward. Deceased patients received a mRS value of 6. The utility values were then combined with length 
of life over the trial follow-up to estimate QALYs for each participant using the area under the curve method.13
Economic Evaluation
A cost-utility analysis was undertaken to compare costs and quality adjusted life years (QALYs) between PASTA 
and SC.14 Cost-effectiveness was expressed as incremental costs per QALY gained. The analysis took the 
perspective of UK NHS and personal social services. As the trial duration of 90 days was the time horizon for the 
economic analysis, discounting of costs and outcomes was not required. Resource use, cost and QALY data were 
analysed using STATA v14·2.
The base-case cost-effectiveness analysis was carried out using the complete case data. Generalised linear model 
regressions with gamma family link function estimated marginal costs and QALY gains whilst controlling for 
age, sex and baseline (pre-stroke) utility clustered by site.13 Non parametric bootstrapping15 with 1000 bootstraps 
was used on the costs and QALYs to estimate the mean difference in costs and QALYs and their 95% CI between 
PASTA pathway and standard care to quantify the degree of uncertainty. Additional analyses without baseline 
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covariate adjustments or bootstrap were carried out using both complete case and available case data to check 
how the mean differences in costs and QALYs differed from the base-case estimates. 
Sensitivity analysis
Stochastic sensitivity analysis, which used the non-parametric bootstrapping technique15 with 1000 bootstraps as 
described earlier, was used to explore the impact of statistical imprecision surrounding the point estimates of costs, 
QALYs and cost-effectiveness. A cost-effectiveness acceptability curve (CEAC)16 was generated using the 
bootstrapped estimates of incremental costs and QALYs to illustrate uncertainty surrounding the cost-
effectiveness estimate. The CEAC demonstrates the probability of each care pathway being cost-effective over a 
range of willingness to pay values. A cost-effectiveness (CE) plane (scatterplot) was also generated to visualise 
the uncertainties in point estimates of incremental costs and QALYs. 
Further sensitivity analyses were conducted to assess the impact of uncertainties surrounding a number of 
assumptions made in the cost-effectiveness analysis, notably the changes in utility estimates and use of imputed 
data. As the base-case cost-effectiveness analysis utilised algorithms for utility values from Whynes et al12 to 
estimate QALYs, the impact of using alternative algorithms from Rivero-Arias et al11 was assessed. A second 
analysis used imputed data where any missing total cost (considered missing if any cost component was missing) 
and utility data were imputed using predictive mean matching (PMM) within the multiple imputation generated 
using chained equations.17 
Subgroup analysis
Participating hospitals were categorised as compliant or non compliant with UK recommendations for provision 
of a specialist thrombolysis on call rota using workforce information available in the National Sentinel Stroke 
Audit Programme Acute Organisational Audit 20162. Compliance was defined as a minimum of six specialists 
trained in emergency stroke care providing a continuous rota without input from non-specialists, so that all 
treatment decisions are made by a stroke specialist from the same service either in person or via telemedicine.18 
Costs, QALYS and cost-effectiveness were calculated as described above for the base-case analysis for each 
subgroup i.e. patients at complaint hospitals (n=7) and patients at non-compliant hospitals (n=8).
RESULTS
From one hundred and twenty one ambulance stations randomised for the trial, 453/817 paramedics from 62 
PASTA stations completed training to participate and 700/723 from 59 SC stations agreed to involvement. During 
the trial enrolment period, 11478 stroke patients conveyed by ambulance were screened by participating HASU 
staff, 1391 were eligible and approached about enrolment, and 1214 gave consent to take part. Of the 1214 enrolled 
patients, 500 were assessed by 242 PASTA trained paramedics (2.1 patients per paramedic) and 714 were assessed 
by 355 SC paramedics (2.0 per paramedic).7 Demographic and clinical characteristics were similar in both groups 
and are reported elsewhere.7
The base-case cost-effectiveness analysis (complete case data), showed no evidence of a difference in QALYs 
between the groups [PASTA: 0.108 (95% CI 0.099 to 0.116); SC: 0.100 (95% CI 0.093 to 0.108); incremental 
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QALY: 0·007 (95% CI -0·003 to 0·018)] over the 90 day follow-up period, however total costs were significantly 
lower in the PASTA group [incremental cost: -£1,473 (95% CI -£2736 to -£219)] (Table 1). When complete case 
data were analysed without baseline adjustment or bootstrapping,  a similar pattern of lower costs in the PASTA 
group but no evidence of a difference in QALYS was seen (Table S3).
Breakdowns of resource utilisation and costs (available case data) are shown in Tables S4 and S5 respectively 
(see supplementary file).  This indicates that lower costs in the PASTA group were in part driven by the lower 
costs of index hospital admissions (~£440) and acute treatment costs, predominantly due to fewer thrombolysis 
treatments (~£300), but there was also a post-discharge saving due to lower requirements for community 
rehabilitation and care homes (~£470). A QALY breakdown is shown in Table S6. 
Sensitivity analysis
A plot of bootstrapped incremental costs and QALYs showed the uncertainties in point estimates of incremental 
costs and QALYs in the base-case analysis and for a majority of iterations the PASTA group was less costly and 
more effective (i.e. dominant over SC)  (Figure 1). Furthermore, over the plausible range of values for society’s 
willingness to pay for a QALY there was over a 97.5% chance that PASTA would be considered cost-effective 
(Figure 2; Table 1). 
[Insert Figure 1] 
[Insert Figure 2]
Further sensitivity analyses showed that the base-case results were in general robust to changes in parameter 
assumptions including the alternative utility algorithms, imputation of missing cost and QALY data.  The PASTA 
pathway still had over 97.5% probability of being considered cost-effective over the range of willingness to pay 
values for these sensitivity analyses (Table 1). 
Subgroup analysis
Thrombolysis guideline compliant and non-compliant hospital results are reported in Table 1. There was no 
evidence of a difference in costs [-423 (-2,220 to 1362)] or in QALYs [0.005 (-0.008 to 0.018)] for those seven 
hospitals compliant with the thrombolysis guidelines. There was less than 74% probability that the PASTA 
pathway would be considered cost-effective over the range of willingness to pay values. However, in the eight 
non-compliant hospitals the costs were significantly lower in the PASTA group [-2,952 (-4,988 to -917)] and there 
was a 99% probability that the PASTA pathway would be considered cost-effective. Uncertainties in the point 
estimates of incremental costs and QALYs in each subgroup are visualised in their respective CE plots (Figures 
3 and 4).
[Insert Figure 3] 
[Insert Figure 4]
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Table 1. Cost-effectiveness of PASTA pathway versus Standard Care
Results are bootstrapped regressed estimates; N= Number of participants observed; Difference estimates: PASTA minus SC.
Probability of PASTA care 
pathway being considered cost-
effective at different threshold 
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DISCUSSION
This economic evaluation has shown that the PASTA trial group had lower costs than standard care and when 
costs were considered alongside data on QALY difference, there was a very high chance that the PASTA 
intervention would be cost-effective across all threshold values for society’s willingness to pay. This finding was 
consistent across all sensitivity analyses. The subgroup analyses indicated that cost-effectiveness was particularly 
likely across services with specialist availability below the level recommended by national guidelines. 
Whilst the lower costs were in part related to fewer thrombolysis treatments in the PASTA group, there were also 
savings observed in other aspects of care including length of stay, rehabilitation and social care. These latter 
findings are consistent with the direction of the QALY difference between the groups, as patients with better 
health would require lower costs for these resources.19  It is surprising, however, that patients were generally in 
better health and incurred fewer care costs in the PASTA group when there was no statistical evidence of a 
difference in thrombolysis rate (primary outcome) and indeed fewer thrombolysis treatments were observed. 
We have previously hypothesised that the counter-intuitive main trial observations of a lower thrombolysis rate 
and better health outcomes in the PASTA group may be explained by a theory that the PASTA intervention led 
to greater caution during patient selection for thrombolysis when the benefit to risk ratio was borderline and 
thereby this avoided futile treatment and lowered the risk of harm from adverse events.7 Other aspects of acute 
care might also have been performed better amongst the intervention group if the PASTA generally reinforced 
adherence to acute care guidelines. As the lower thrombolysis rate was particularly evident across services with 
specialist availability below the level recommended by national guidelines, the relative inexperience of non-
specialists may routinely lead to over- rather than under-treatment of borderline cases when weighing up complex 
information under time pressure. Such behaviour may have been moderated by the more detailed and structured 
content of the enhanced paramedic assessment including details about bleeding risk (e.g. recent surgery and 
anticoagulant medication) and pre-stroke dependency7. In non-stroke specialties there is already evidence that 
simple tools to structure paramedic to ED handover20, 21 and multidisciplinary care process checklists22, 23 can 
standardise communication of key information and improve the quality of care. As the trial findings were 
unexpected, we did not collect detailed information about individual treatment decisions and additional 
interventions which would be needed to confirm our theory, however, we believe that both the main and post-hoc 
health economic analyses are consistent with and provide support to this suggestion.
Interpretation of trials with a neutral primary outcome yet dominant cost-effectiveness is variable with some 
authors reporting that the intervention should be adopted but others stating uncertainty or favouring the control.24 
The PASTA trial is further complicated when the counter-intuitive nature of the main trial observations are 
considered. The results of the health economic analyses could of course be due to chance as the study was not 
powered to detect differences in costs, QALYs and cost-effectiveness. However, as PASTA was a large trial 
across multiple hospital sites and confidence intervals for costs and QALYs were relatively narrow, there is a very 
high likelihood that PASTA intervention would be considered cost-effective even though the underlying 
mechanism requires further investigation. As cost-effectiveness was shown for >97.5% of willingness to pay 
scenarios, this is analogous to a one sided p value  <0.025 that cost-effectiveness would be acceptable.  
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The main strength of our study was the use of a randomised controlled cluster design involving large numbers of 
patients across multiple HASUs operating under the same National Clinical Guidelines and costing frameworks. 
The main limitation of the economic analysis is that utility values were estimated using published algorithms for 
mapping mRS scores on to the EQ-5D rather than being based on responses to the EQ-5D collected directly from 
participants. However, the algorithm used has been well validated and it is reassuring that conclusions did not 
change when an alternative utility algorithm was applied. Although the QALY difference found was small and 
therefore potentially prone to measurement error, the value reflects the entire trial population whereas only a 
proportion of patients received thrombolysis, which itself is a treatment that only benefits or harms a proportion 
of those who are treated. Consequently, it may not be surprising that the QALY difference found was small. In 
addition, follow up was short term at 90 days whereas QALY gain may be greater over a longer period as patients 
in better health by day 90 are likely to be those with a changed recovery trajectory which would translate into 
additional further gain over time25, 26. It should also be acknowledged that the study took a UK personal social 
care perspective, and the findings may not apply in other healthcare settings.
This is the first study to formally evaluate the 90-day cost-effectiveness of a paramedic-led process to improve 
outcomes during emergency care of stroke patients and illustrates the importance of considering economic 
consequences of complex interventions.  Further investigation is required to understand the specific effects upon 
clinical decisions and care delivery, but our data indicate that the PASTA pathway is likely to be a cost-effective 
intervention, particularly if it is deployed in areas where hospital stroke specialist availability is limited.
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Figures
Figure 1: Cost-effectiveness plane (base-case analysis)
Figure 2. Cost-effectiveness acceptability curve (CEAC) (base-case analysis)
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